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Objectives. This study sought to examine the influence of time
to reperfusion on myocardial salvage.
Background. Major trials of reperfusion therapy for myocardial
infarction (MI) have demonstrated improved outcome for patients
achieving earlier reperfusion. However, some patients experience
significant benefit despite delayed reperfusion.
Methods. Fifty-five patients with a first anterior MI underwent
successful reperfusion therapy (angioplasty or thrombolysis).
Technetium-99m (Tc-99m) sestamibi was injected before reperfu-
sion therapy and again at hospital discharge to determine the
myocardial salvage index for each patient. Residual flow to the
infarct territory was assessed by the nadir of the Tc-99m sestamibi
count–profile curve.
Results. The salvage index showed wide variability (range
20.04 to 1.0), and extreme values were seen in 34.5% of the group
(<0.10 in 9%, >0.90 in 25%). A high salvage index was associated
with reperfusion therapy before 2 h (p 5 0.02) or good residual
blood flow (p < 0.01). For the 10 patients who received reperfu-
sion therapy within 2 h, residual blood flow was not correlated
with salvage (p 5 0.12). For the 45 patients treated after 2 h,
residual blood flow correlated significantly with salvage (r 5 0.57,
p < 0.0001). There was a significant interaction (p < 0.05) between
residual blood flow and time to therapy, indicating that the effect of
each variable on salvage depended on the value of the other. Multiple
historic and hemodynamic variables were examined, but none dem-
onstrated any association with residual flow or myocardial salvage.
Conclusions. In patients with acute MI, successful reperfusion
therapy within 2 h is associated with the greatest degree of
myocardial salvage. For patients treated after 2 h, residual blood
flow to the infarct-related territory appears to be the most
important determinant of myocardial salvage.
(J Am Coll Cardiol 1998;31:1246–51)
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Reperfusion therapy using either intravenous thrombolytic
agents or primary percutaneous transluminal coronary angio-
plasty (PTCA) is established therapy for acute myocardial
infarction (AMI) (1–5). In experimental (6–8) and clinical studies
(1–5), time to successful reperfusion is a critical determinant of
outcome. Experimental models have demonstrated that other
factors playing critical roles in ultimate infarct size include extent
of myocardium at risk, myocardial metabolic demand and collat-
eral blood flow to the infarct-related region (6–8).
Technetium-99m sestamibi (Tc-99m) has been used effec-
tively in the past to measure residual and collateral blood flow,
myocardium at risk and infarct size in clinical AMI (9–12). The
minimal redistribution of this agent, despite restoration of
hyperemic blood flow after coronary artery reperfusion, allows
for measurement of these indexes without interrupting reper-
fusion therapy (13,14).
Previous work using Tc-99m in clinical AMI has shown a
poor linear correlation between time to reperfusion therapy
and final infarct size (15). Although reperfusion therapy re-
ceived within 2 h is associated with the greatest benefit (5),
many patients receiving late therapy also have significant
degrees of myocardial salvage. In a recent meta-analysis of 22
placebo-controlled trials of thrombolytic therapy for AMI, a
nonlinear relation was demonstrated between time to reperfu-
sion and mortality (16). In that study, the beneficial effect of
thrombolytic therapy was substantially higher in patients
treated within 2 h of symptom onset. In patients presenting
after 2 h, the effect of time to therapy on mortality was less.
To identify variables that are associated with myocardial
salvage in patients with AMI, we measured time to reperfusion
therapy, myocardial salvage, residual blood flow to myocar-
dium at risk, hemodynamic data and clinical variables in 55
patients presenting with acute anterior MI who received
successful reperfusion therapy. We hypothesized that time to
reperfusion therapy would be the major determinant of myo-
cardial salvage for those patients receiving such therapy within
2 h. For patients receiving reperfusion therapy after 2 h, we
hypothesized that the degree of residual blood flow to the
myocardium at risk, either through collateral vessels or resid-
ual anterograde flow in the infarct-related artery (IRA), would
be the most important determinant of myocardial salvage.
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Methods
Study group. The study group included a consecutive series
of patients enrolled in a prospective study of Tc-99m in AMI
who met the following inclusion criteria: 1) chest pain lasting
$30 min; 2) electrocardiographic (ECG) ST segment elevation
of $0.1 mV in at least two consecutive anterior precordial
leads (leads V1 to V4); and 3) successful reperfusion therapy
with either PTCA (n 5 32) or thrombolysis (n 5 23), defined
as restoration of Thrombolysis in Myocardial Infarction
(TIMI) flow grade 3 on the coronary angiogram (17). Ninety-
one patients met these inclusion criteria.
Patients were excluded because of 1) ECG or historic
evidence of a previous myocardial infarction (n 5 9); 2) clinical
instability or death preventing transportation to the nuclear
cardiology laboratory (n 5 17); 3) anterograde flow in the IRA
before direct PTCA (n 5 5); 4) no measurable perfusion defect
(myocardium at risk) on the early perfusion study (n 5 1); 5)
technical difficulties precluding radionuclide or angiographic
collateral grading (n 5 3); and 6) hypertrophic obstructive
cardiomyopathy (n 5 1). Thus, 55 patients formed the study
group (42 men, 13 women; mean age 61 6 11 years, range 38
to 80). Forty of these patients were included in a previous study
of infarct size (15).
Clinical care. The use of aspirin, heparin, nitroglycerin and
beta-blockers was in accordance with standard clinical practice
and was determined by the attending cardiologist or clinical
trial protocol.
Radionuclide studies. Each patient received 20 to 30 mCi
of Tc-99m intravenously before reperfusion therapy and again
before hospital discharge. Thirty images were obtained for 40 s
each, every 6° over an arc of 180° from the 45° right anterior
oblique to the 45° left posterior oblique projection.
Images were reconstructed using standard back-projection
algorithms and a Ramp-Hanning filter. Short-axis slices of the
left ventricle were obtained every 6 mm and normalized to the
peak counts in the heart. Circumferential count profiles were
generated for apical, midventricular, basal and two intermedi-
ate slices (midway between the apical-midventricular and
basal-midventricular slices).
Quantification of the extent of LV perfusion defect has
been previously described (15) and validated in phantom
models (18), animal models (19) and explanted human hearts
(20). Briefly, pixels containing ,60% of peak counts were
considered abnormal and part of the perfusion defect. Assum-
ing the ventricle consists of a hollow cylinder and hollow cone
(for the apical slice), the relative volume of each geometric
figure could be estimated using the radius of each representa-
tive slice and standard geometric formulas (18). The extent of
the defect is expressed as a percentage of the left ventricular
(LV) mass. The standard deviation of the difference between
repeat measurements using this method is 3% of the left
ventricle (21).
Myocardial salvage. The perfusion defect on the acute
study represents the amount of myocardium at risk, and the
discharge defect corresponds to the final infarct size. The
difference between the acute and discharge defects is a mea-
sure of myocardial salvage. The salvage index is a measure of
treatment efficacy, which allows for comparisons among in-
farcts of different sizes. It is derived by dividing the difference
between the acute and discharge defect sizes (myocardial
salvage) by the acute defect size (myocardium at risk) (22). A
salvage index of 1.0 indicates an ideal treatment effect, whereas
0 indicates no treatment benefit.
Radionuclide assessment of residual blood flow. This was
assessed using the nadir of the five short-axis Tc-99m sestamibi
circumferential count–profile curves from the acute images.
The nadir is the lowest ratio of minimal counts per pixel over
the maximal counts per pixel in the five short-axis slices. The
nadir represents residual blood flow to the infarct zone. The
technique does not distinguish between residual flow from the
IRA or collateral blood flow. The basic assumption of this
technique is that the depth of the profile curve is inversely
proportional to residual blood flow in the infarct territory. The
nadir of the count–profile curve has been previously validated
and shown to correlate significantly with angiographic esti-
mates of collateral flow in experimental (23) and clinical
infarcts (15).
In patients with anterior MI undergoing acute angiography
before direct PTCA, we have shown that about one-half have
Rentrop grade 2 or 3 collateral vessels (15). In the present
study, where most patients did not undergo acute angiography,
we defined “good” collateral vessels as a nadir greater than the
median, and “poor” collateral vessels as a nadir less than or
equal to the median.
Historical and hemodynamic variables. The following
were tested for an association with myocardial salvage: age,
gender, previous angina, history of hypertension (n 5 19),
diabetes mellitus (n 5 6), chronic beta-blocker therapy (n 5
6), smoking status, presenting heart rate, presenting systolic
blood pressure and presenting rate–pressure product. Angina
was analyzed with respect to its presence and duration. Left
ventricular ejection fraction (LVEF) was measured at hospital
discharge with equilibrium radionuclide angiography using
standard techniques (24).
Statistics. Data were expressed as the mean value 6 SD or
the median value with percentiles when the groups were
skewed. Simple linear regression analysis was done to compare
residual blood flow (nadir) with the salvage index. The latter
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
ANOVA 5 analysis of variance
ECG 5 electrocardiogram, electrocardiographic
GUSTO 5 Global Use of Strategies to Open Occluded Arteries
IRA 5 infarct-related artery
LV 5 left ventricular
LVEF 5 ejection fraction
PTCA 5 percutaneous transluminal coronary angioplasty
Tc-99m 5 technetium-99m
TIMI 5 Thrombolysis in Myocardial Infarction
1247JACC Vol. 31, No. 6 MILAVETZ ET AL.
May 1998:1246–51 TIME TO THERAPY AND MYOCARDIAL SALVAGE IN MI
two variables were compared with respect to time to therapy
using Spearman and linear correlation. Two-way analysis of
variance (ANOVA) was used to test for an interaction effect
between residual blood flow and time with respect to salvage
index. Linear regression analysis, one-factor ANOVA, an
unpaired t test and a chi-square test were used, as appropriate,
to test the association of various clinical variables with residual
blood flow and salvage index.
Results
Time to reperfusion therapy. For all 55 patients, time to
reperfusion therapy was 320 6 285 min (range 88 to 1290). For
patients receiving thrombolytic therapy, time from onset of
chest pain to initiation of thrombolytic infusion was 188 6
91 min (range 88 to 395). Seven patients had thrombolytic
therapy initiated within 2 h. Thirty-two patients received
primary PTCA. In these patients, the time from the onset of
chest pain to first balloon inflation was 415 6 337 min (range
89 to 1290). Three patients had PTCA within 2 h.
Myocardial salvage. The early perfusion defect size, or
myocardium at risk, was 47 6 14% of the LV (range 10% to
73%). Tomographic quantitation of discharge infarct size
measured 22 6 20% of the LV (range 0% to 55%). The salvage
index showed wide variability with a skewed distribution (Fig.
1). The median value for the salvage index was 0.60, with 25th
and 75th percentiles of 0.26 and 0.93, respectively (range
20.04 to 1.0). Five patients (9.1%) had a salvage index ,0.10,
suggesting minimal treatment benefit. Fourteen patients
(25.5%) had a salvage index .0.90, suggesting nearly complete
myocardial salvage with minimal infarction (Table 1).
Extreme values of salvage index (Table 1). When the five
patients with a low salvage index (,0.10) were compared with
the 14 patients with a high salvage index (.0.90), there was a
highly significant difference in final infarct size and LVEF at
discharge between the two groups. Treatment modality and
time to treatment did not differ between the two groups. Of the
five patients with a low salvage index, none received reperfu-
sion therapy within 2 h. Of the 14 patients with a high salvage
index, five received reperfusion therapy within 2 h (p 5 0.17
compared with low salvage index group). None of the five
patients with a low salvage index had good residual blood flow.
In contrast, 11 of 14 patients in the high salvage index group
had good residual blood flow (p 5 0.005 vs. low salvage index
group). Three patients with a high salvage index and poor
residual blood flow were treated at 95 min, 128 min and
298 min. Thus, 12 of the 14 patients with a high salvage index
had either reperfusion therapy within 2 h or good residual
blood flow. None of the five patients with a low salvage index
had early therapy or good residual blood flow (p 5 0.005 vs.
low salvage index group).
Residual blood flow. For all 55 patients, the nadir was
0.22 6 0.13, with a median value of 0.19. Twenty-six patients
had a nadir of .0.19 and were classified as having good
residual blood flow; 29 patients had a nadir of #0.19 and were
classified as having poor residual blood flow. For all patients,
residual blood flow correlated weakly but significantly with the
salvage index (r 5 0.57, p 5 0.0001). For the 10 patients who
received reperfusion therapy within 2 h, residual blood flow did
not correlate with the salvage index (rho 0.51, p 5 0.12) (Fig.
2A). However, collateral blood flow did correlate with the
salvage index for the 45 patients treated after 2 h (r 5 0.57, p 5
0.0001) (Fig. 2B). There was a significant difference between
the two time groups with respect to the relation between
collateral blood flow and salvage index, using analysis of
covariance (p 5 0.035).
Multivariable analysis. Using two-way ANOVA, both time
to therapy (,2 h vs. .2 h) (F 5 8.4, p , 0.006) and residual
blood flow (good vs. poor) (F 5 10.3, p , 0.002) were
independently associated with the salvage index. A significant
interaction (F 5 4.1, p , 0.05) was found between residual
blood flow and time to therapy, indicating that the effect of
time to therapy (,2 h vs. .2 h) and residual blood flow (good
vs. poor) on salvage depended on the value of the other (Fig.
3). Patients with either good residual blood flow or time to
therapy ,2 h, or both, had a high salvage index. The 24
patients with poor residual blood flow and treatment after 2 h
had the lowest salvage index values (0.32 6 0.27).
Clinical variables. Age, gender, previous angina, hyperten-
sion, diabetes mellitus, smoking status, long-term beta-blocker
Figure 1. Histogram of salvage index for all 55 patients. The salvage
index varied widely, with a dramatically skewed distribution.
Table 1. Comparison of Variables of 19 Patients With Extreme
Myocardial Salvage (,10% vs. .90% salvage index)
Salvage Index
p Value
,0.10
(n 5 5)
.0.90
(n 5 14)
Discharge LVEF (%)* 30 6 14 55 6 8 0.0004
Infarct size (% of LV)* 49 6 3 1 6 1 0.0001
Angioplasty 60% 42% NS
Time to treatment (h) 4.6 4.3 0.90
Reperfusion therapy ,2 h 0/5 5/14 0.17
Good residual blood flow 0/5 11/14 0.005
Good residual blood flow
or reperfusion ,2 h
0/5 12/14 0.002
*Data presented are mean value 6 SD, median or number or percent of
patients. LV 5 left ventricle; LVEF 5 left ventricular ejection fraction.
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use, acute heart rate or acute rate–pressure product were not
found to be associated with the myocardial salvage index or
collateral grade (Table 2). Acute systolic blood pressure
weakly correlated (r 5 0.32, p 5 0.02) with the salvage index,
but this finding is of doubtful significance given the 30 com-
parisons that were performed. Of all 55 patients, the discharge
LVEF was 44 6 12% (range 16% to 69%). The discharge
LVEF was significantly higher among those patients treated
within 2 h (52 6 9% vs. 42 6 12%, p 5 0.03).
Discussion
This study lends insight into the variable clinical outcomes
of patients who receive successful reperfusion therapy for
AMI. In such patients, myocardial salvage is optimal in the
presence of either extremely early therapy (,2 h from symp-
tom onset) or adequate residual blood flow (collateral blood
flow or anterograde flow) to the infarct-related territory. In
patients treated after 2 h, the most powerful predictor of
myocardial salvage was the presence of good residual blood
flow, as assessed by radionuclide angiography. No historic or
hemodynamic factors accurately predicted myocardial salvage.
Timing and salvage. The finding that early reperfusion
therapy is associated with improved myocardial salvage is
conceptually consistent with the results from large clinical
trials of reperfusion strategies in AMI (1–5). Clinical trials
have clearly demonstrated a relation between early therapy
and reduced mortality. More recently, this has been shown to
be nonlinear, with a much greater mortality benefit if therapy
is administered within 2 h of the onset of chest pain (16). A
report from the Global Use of Strategies to Open occluded
arteries (GUSTO) data base showed that the greatest benefit
from thrombolytic therapy was experienced by patients receiv-
ing treatment within 2 h. At 2 h an inflexion point was apparent
in the curve relating mortality to time to therapy (5).
Although the benefits of reperfusion therapy are greatest
when administered early, experimental data have shown that
other major determinants of infarct size include the amount of
myocardial at risk, myocardial metabolic demand and degree
of collateral blood flow to the infarct territory (6,24).
Our results confirm the importance of collateral blood flow
in clinical infarction and suggest that adequate collateral flow
to an infarct territory results in significant myocardial salvage.
Conversely, in patients with poor collateral blood flow, unless
reperfusion therapy was received within 2 h, myocardial sal-
vage was extremely poor. Thus, the presence or absence of
collateral blood flow explains both the skewed appearance of
the salvage index, as seen in Figure 1, and the observation of
extremes of salvage index seen in our patient group, as
outlined in Table 1. Our data demonstrate that when reperfu-
sion therapy is administered after 2 h, the major determinant
Figure 2. Relation of residual blood flow and salvage index for
patients with reperfusion therapy initiated (A) within 2 h (n 5 10, r 5
0.48, p 5 0.16) and (B) after 2 h (n 5 45, r 5 0.57, p 5 0.0001).
Figure 3. Relation between time to reperfusion therapy (Rx) and
residual blood flow on myocardial salvage index. Each variable,
including their interaction, was significant.
Table 2. Assessment of Historical and Hemodynamic Variables
Potentially Associated With Residual Blood Flow and
Myocardial Salvage
p Value
Residual
Blood Flow Salvage Index
Age 0.56 0.96
Gender 0.98 0.95
Angina 0.38 0.33
Hypertension 0.91 0.57
Diabetes mellitus 0.20 0.45
Smoking 0.08 0.38
Beta-blockers (long term) 0.34 0.86
Acute HR 0.62 0.18
Acute SBP 0.12 0.02
Acute RPP 0.48 0.49
HR 5 heart rate; RPP 5 rate–pressure product; SBP 5 systolic blood
pressure.
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of salvage is the extent of residual blood flow to the infarct
zone.
The nonlinear relation between time to reperfusion therapy
and mortality, as recently reported in a meta-analysis of 22
placebo-controlled trials, may be interpreted based on our
findings in Figure 3 (16). Of all patients with acute MI, those
with good residual blood flow to the infarct zone will have a
low rate of loss of viable myocardium. In contrast, those with
poor collateral vessels will show an early and rapid loss of
myocardium.
None of the clinical variables in this study were predictive of
therapeutic efficacy. Although this may be due to a lack of
statistical power, this finding is similar to data from the TIMI
phase I trial in which numerous variables failed to correlate
with angiographic collateral vessels in the initial hours of
infarction (25). Time to therapy was dichotomized a priori at
2 h in this study, based on previous animal (26) and clinical
(27) studies. Because all patients in this study had “successful”
reperfusion, any comparison of an open versus closed artery
could not be made. Our study supports the importance,
however, of residual blood flow in patients with AMI who are
treated successfully with reperfusion therapy.
Study limitations. Only survivors of anterior infarcts with
successful reperfusion therapy were examined. This group was
chosen to minimize the effects of measurement error, as
anterior infarcts have greater myocardium at risk (22,23), and
because Tc-99m estimates of residual flow are more closely
correlated with angiographic grading of collateral vessels in
anterior infarcts (15). Both radionuclide and angiographic
estimates of residual blood flow are crude, although angio-
graphic grading systems have correlated closely with intraop-
erative measurements of collateral flow and retrograde perfu-
sion pressure (28). In addition to collateral artery blood flow,
radionuclide angiography may also reflect anterograde flow in
the IRA.
The exact timing of successful reperfusion cannot be known
with certainty in the 23 patients who underwent thrombolysis.
Intermittent spontaneous reperfusion and the effects of aspirin
and heparin on infarct–vessel patency are difficult to assess. In
addition, silent reocclusion may be undetected in some pa-
tients and may have affected the final infarct size. Finally,
because only 55 patients were examined, the study lacks the
statistical power of a larger trial.
Despite these limitations, these data reinforce the impor-
tance of very early (,2 h) reperfusion and demonstrate that
the efficacy of late reperfusion is primarily determined by the
extent of residual blood flow to the infarct territory. Current
investigations directed toward understanding the development
of collateral circulation may ultimately help to limit infarct size
and thereby improve long-term clinical outcome.
We thank Rose Busta for assistance in preparing this report.
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